<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05622812</url>
  </required_header>
  <id_info>
    <org_study_id>05DF2209</org_study_id>
    <nct_id>NCT05622812</nct_id>
  </id_info>
  <brief_title>Effectiveness and Safety of Restylane Lyft Lidocaine for Jawline Definition</brief_title>
  <official_title>A Randomized, Evaluator-blinded, Parallel Group, no Treatment Controlled, Multicenter Study to Evaluate Effectiveness and Safety of Restylane Lyft Lidocaine for Jawline Definition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galderma R&amp;D</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galderma R&amp;D</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate effectiveness and safety of Restylane Lyft Lidocaine for&#xD;
      Jawline definition&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, evaluator-blinded, parallel group, no treatment controlled, multicenter study&#xD;
      to evaluate effectiveness and safety of Restylane Lyft Lidocaine for Jawline definition in&#xD;
      Canada&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 16, 2023</start_date>
  <completion_date type="Anticipated">July 19, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 22, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effectiveness of Restylane Lyft Lidocaine versus a no treatment control in jawline definition as measured by the Galderma Jawline Scale</measure>
    <time_frame>3 Months</time_frame>
    <description>Scale rating is 0-4, where higher score = more volume deficiency in the treatment area</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effectiveness of Restylane Lyft Lidocaine on the Galderma Jawline Scale</measure>
    <time_frame>Baseline, 6, 9, and 12 Months</time_frame>
    <description>Scale rating is 0-4, where higher score = more volume deficiency in the treatment area</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effectiveness of Restylane Lyft Lidocaine on the Global Aesthetic Improvement Scale (GAIS)</measure>
    <time_frame>Baseline, 3, 6, 9, and 12 Months</time_frame>
    <description>Scale rating ranges from very much improved to very much worse appearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effectiveness of Restylane Lyft Lidocaine on Subject Satisfaction Questionnaire (SSQ)</measure>
    <time_frame>3, 6, 9, and 12 Months</time_frame>
    <description>Questionnaire rating ranges from very satisfied to very dissatisfied with aesthetic outcome and treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Jawline Definition</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Initial Restylane Lyft Lidocaine injection and one optional touch-up treatment at 1 month after treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No-treatment control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Optional treatment will be administered at 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Restylane Lyft Lidocaine</intervention_name>
    <description>Treatment for Jawline definition</description>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female adults willing to comply with the requirements of the study and&#xD;
             providing a signed written informed consent&#xD;
&#xD;
          -  Consent the use of facial images for marketing purposes and educational material&#xD;
&#xD;
          -  Subject with moderate to very severe (Grade 2 to 4) on the GJS&#xD;
&#xD;
          -  Subject is willing to abstain from any other facial, submental, and/or neck aesthetic&#xD;
             procedure(s) or implant&#xD;
&#xD;
          -  Female of childbearing potential with a negative urine pregnancy test before treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects presenting with known/previous allergy or hypersensitivity to hyaluronic acid&#xD;
             (HA) filler, lidocaine or other amide-type local anesthetics&#xD;
&#xD;
          -  Subjects presenting with known/previous allergy or hypersensitivity to streptococcal&#xD;
             proteins&#xD;
&#xD;
          -  Subject with bleeding disorders or taking thrombolytics or anticoagulants&#xD;
&#xD;
          -  Prior surgical procedure in the treatment area&#xD;
&#xD;
          -  History of other facial treatment/procedure in the previous 6 months HA in or near the&#xD;
             intended treatment site&#xD;
&#xD;
          -  Presence of any disease or lesions near or on the area to be treated&#xD;
&#xD;
          -  Presence of any condition, in the opinion of the Treating Investigator, makes the&#xD;
             subject unable to complete the study per protocol&#xD;
&#xD;
          -  Women who are pregnant or breast feeding, or women of childbearing potential who are&#xD;
             not practicing adequate contraception or planning to become pregnant during the study&#xD;
             period&#xD;
&#xD;
          -  Study site personnel, close relatives of the study site personnel, employees, or close&#xD;
             relatives of employees at the Sponsor Company&#xD;
&#xD;
          -  Participation in any other interventional clinical study within 30 days before&#xD;
             treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Galderma R&amp;D</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Galderma R&amp;D</last_name>
    <phone>1-817-961-5000</phone>
    <email>aestheticclinicaltrials@galderma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Galderma Research Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z4E1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Research Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H4E1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Research Site</name>
      <address>
        <city>Burlington</city>
        <state>Ontario</state>
        <zip>L7N3N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Research Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6H5L5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Research Site</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6J7W5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Research Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5R3N8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Research Site</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W5L7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Research Site</name>
      <address>
        <city>Woodbridge</city>
        <state>Ontario</state>
        <zip>L4L8E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Research Site</name>
      <address>
        <city>Westmount</city>
        <state>Quebec</state>
        <zip>H3Z1C3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Investigator</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>November 7, 2022</study_first_submitted>
  <study_first_submitted_qc>November 11, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 21, 2022</study_first_posted>
  <last_update_submitted>April 4, 2023</last_update_submitted>
  <last_update_submitted_qc>April 4, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

